Using linkage studies combined with whole-exome sequencing to identify novel candidate genes for familial colorectal cancer by Toma, Claudio et al.

Using linkage studies combined with whole-exome sequencing
to identify novel candidate genes for familial colorectal cancer
Claudio Toma1,2†, Marcos Díaz-Gay3†, Sebastià Franch-Expósito3, Coral Arnau-Collell3, Bronwyn Overs1,2, Jenifer Muñoz3,
Laia Bonjoch3, Yasmin Soares de Lima3, Teresa Ocaña3, Miriam Cuatrecasas4, Antoni Castells3, Luis Bujanda5,
Francesc Balaguer3, Joaquín Cubiella 6, Trinidad Caldés7, Janice M. Fullerton1,2 and Sergi Castellví-Bel 3
1Neuroscience Research Australia, Sydney, Australia
2School of Medical Sciences, University of New South Wales, Sydney, Australia
3Gastroenterology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de
Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Clínic, University of Barcelona, Barcelona, Spain
4Pathology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de
Enfermedades Hepáticas y Digestivas (CIBERehd) and Tumor Bank-Biobank, Hospital Clínic, Barcelona, Spain
5Gastroenterology Department, Hospital Donostia-Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y
Digestivas (CIBERehd), Basque Country University (UPV/EHU), San Sebastian, Spain
6Gastroenterology Department, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Sanitaria Galicia Sur, Centro de
Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ourense, Spain
7Molecular Oncology Laboratory, Hospital Clinico San Carlos, CIBERONC (Centro de Investigacion Biomedica en Red de Cancer), IdISSC, Madrid, Spain
Colorectal cancer (CRC) is a complex disorder for which the majority of the underlying germline predisposition factors remain
still unidentified. Here, we combined whole-exome sequencing (WES) and linkage analysis in families with multiple relatives
affected by CRC to identify candidate genes harboring rare variants with potential high-penetrance effects. Forty-seven affected
subjects from 18 extended CRC families underwent WES. Genome-wide linkage analysis was performed under linear and
exponential models. Suggestive linkage peaks were identified on chromosomes 1q22–q24.2 (maxSNP = rs2134095;
LODlinear = 2.38, LODexp = 2.196), 7q31.2–q34 (maxSNP = rs6953296; LODlinear = 2.197, LODexp = 2.149) and 10q21.2–
q23.1 (maxSNP = rs1904589; LODlinear = 1.445, LODexp = 2.195). These linkage signals were replicated in 10 independent
sets of random markers from each of these regions. To assess the contribution of rare variants predicted to be pathogenic, we
performed a family-based segregation test with 89 rare variants predicted to be deleterious from 78 genes under the linkage
intervals. This analysis showed significant segregation of rare variants with CRC in 18 genes (weighted p-value > 0.0028).
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Protein network analysis and functional evaluation were used to suggest a plausible candidate gene for germline CRC
predisposition. Etiologic rare variants implicated in cancer germline predisposition may be identified by combining traditional
linkage with WES data. This approach can be used with already available NGS data from families with several sequenced
members to further identify candidate genes involved germline predisposition to disease. This approach resulted in one
candidate gene associated with increased risk of CRC but needs evidence from further studies.
What’s new?
Inherited genetic factors are thought to account for more than one-third of colorectal cancer (CRC) cases. Most predisposing
genetic factors, however, remain unidentified. Here, genome-wide linkage analysis using whole-exome sequencing (WES) data
was performed in families with marked CRC aggregation. The combined linkage-sequencing approach identified possible
linkage peaks on chromosomes 1q22-q24.2, 7q31.2-q34, and 10q21.2-q23.1. Analyses of potentially pathogenic variants
revealed significant segregation of rare variants in 18 genes, while functional analyses identified a plausible candidate gene
for germline CRC predisposition. The findings underscore the utility of linkage analysis employing WES for the discovery of
candidate genes for disease predisposition.
Introduction
Colorectal cancer (CRC), like other complex diseases, is caused by
both genetic and environmental factors. Although environmental
causes such as smoking and diet are without doubt risk factors for
CRC, studies in twins show that 35% of the variability in suscepti-
bility corresponds to inherited genetic factors.1,2 Approximately
6% of cases present with a strong family aggregation and belong
to the well-known forms of hereditary CRC, caused by germinal
mutations in APC, MUTYH or the DNA mismatch repair genes.
In addition, 30% of CRC cases show family history outside of
these known hereditary CRC genes and are categorized as familial
CRC, whereas the remaining 65% are classified as sporadic CRC
cases.3
In the past decade, several studies attempted to identify new
germline genetic risk factors for CRC by using genetic linkage
analysis. Indeed, the first studies pointed to loci on chromo-
somes 9q22 and 3q22 which contained putative susceptibility
variants implicated in the disease.4,5 Additional reports pointed
to loci on other chromosomes including 11q, 14q and 22q,6
7q31,7 10q23,8 4q21, 8q13, 12q24 and 15q22,9 and 4p16.3,
9q31.1, 17p13.2 and Xp22.33.10 However, previous studies were
not able to clearly identify candidate genes that were responsible
for those linkage signals. On the other hand, genome-wide asso-
ciation studies have achieved greater success in pinpointing addi-
tional germline factors by discovering up to 100 common, low-
penetrance genetic variants involved in susceptibility to CRC.11,12
Next-generation sequencing (NGS) technologies have facili-
tated the identification of genes involved in disease predisposi-
tion.13,14 Sequencing directed to genome coding regions (exons)
or whole-exome sequencing (WES) has become the most fruitful
application of NGS in translational biomedicine.15 Recently,
NGS has discovered germinal mutations in genes that cause
hereditary CRC, such as POLE and POLD1 or NTLH1.16,17 Sev-
eral other studies using WES on familial CRC cohorts have pro-
posed several candidate genes for germline predisposition but
have also evidenced that the number of candidate variants
remains too high after NGS and should be reduced by other
means.18–21
Linkage analysis studies performed with common polymor-
phisms from WES data have been suggested as a cost-effective
strategy to simultaneously identify linkage regions and then
focus on variant-level gene mapping within these intervals.22–24
This approach has already been used successfully to identify
candidate genes in several diseases,25,26 but its strength is yet to
be determined in complex disorders with genetic heterogeneity.
In the present study, we combined WES and linkage analy-
sis in 18 multiplex or extended families with unaffiliated CRC
aggregation. Sequencing data from 47 patients were used to
identify rare variants with potential high-penetrance effects
from the identified linkage intervals. By doing so, we aim to
identify novel candidate genes involved in germline CRC pre-
disposition, adding to the knowledge base for future genetic
counseling and prevention protocols.
Materials and Methods
Study participants
Eighteen multiplex and extended families with at least three
affected relatives with unaffiliated strong CRC aggregation were
selected from a previously described cohort of 38 families
(Fig. 1).19,27,28 Families were selected based on the following
criteria: three or more relatives with CRC, two or more consecu-
tive affected generations and at least one CRC diagnosed before
the age of 60. The presence of germline alterations in well-
known genes related to hereditary CRC syndromes (APC,
MUTYH and the DNA MMR genes) were previously discarded
for all probands. Tumors from probands were microsatellite sta-
ble and negative for MLH1 methylation. High-risk adenomas
were adenomas with villous histology or high-grade dysplasia or
≥10 mm in size). Our study was approved by the institutional
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Figure 1. Pedigree structures of the 18 CRC multiplex and extended families examined in our study. Males are indicated with squares, females
with circles and diagnosis are shown by dark shading (full, patients diagnosed with colorectal cancer, CRC, left quarter, patients diagnosed with
high-risk adenoma; half, patients diagnosed with any other type of cancer detailed in the figure legend; unshaded, unaffected individuals or
unknown). Patients analyzed by whole-exome sequencing are indicated by an asterisk, and all subjects with DNA available are underlined.
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ethics committee and written informed consent was obtained in
all cases.
WES data
The entire cohort had germline WES data available from previous
studies.19,27,28 The group studied herein comprised 47 patients
from 18 families, 41 were diagnosed with CRC, two with high-
risk colorectal adenoma, and four with other type of cancer. The
six selected individuals with high-risk adenoma or other neo-
plasms were offspring of patients diagnosed with CRC. Briefly,
WES was performed using the HiSeq2000 platform (Illumina,
San Diego, CA) and SureSelectXT Human All Exon V4 or V5
for exon enrichment (Agilent, Santa Clara, CA). Indexed libraries
were pooled and massively parallel sequenced using a paired-end
2 × 75 bp read length protocol. Burrows–Wheeler Aligner
(BWA-MEM) was used for read mapping to the human reference
genome (build hs37d5, based on NCBI GRCh37).29 PCR dupli-
cates were discarded using the MarkDuplicates tool from Picard
and then indel realignment and base quality score recalibration
were performed with the Genome Analysis Toolkit (GATK).30
The HaplotypeCaller GATK tool was used for variant calling.30
Linkage analysis procedures
Genotypes were called from aligned WES reads using SAMtools
pileup and filtered to include haplotype-informative markers
(HapMap CEU population) using LINKDATAGEN.31 WES-
derived genotypes were used to confirm familial relationships
by pair-wise identity-by-descent (IBD) using PLINK,32 and Z0,
Z1 and Z2 values were obtained. All genotyped-derived genetic
relationships were consistent with demographic information
from the clinical records.
A linkage study was performed using 5,723 WES-derived
single-nucleotide polymorphisms (SNPs) from 22 autosomal
chromosomes (n = 5,563 SNPs) and the X chromosome
(n = 160 SNPs) across all 18 families. Nonparametric linkage
(NPL) analyses were performed using the “all” statistic
implemented in Merlin,33 under the Kong and Cox linear
(LOD) and exponential (ExLOD) models. All genotyped indi-
viduals in our study were affected and, where possible, from
the most distant branches of each pedigree. Pedigree structures
and diagnoses are detailed in Figure 1. The results of the
genome-wide linkage scan under both linear and exponential
models were plotted using the “lodplot” R package (https://
cran.r-project.org/src/contrib/Archive/lodplot).
Fine mapping of linkage peaks
A LOD score threshold of greater than 2 was considered as sugges-
tive evidence of linkage. A fine-mapping study was performed
including additional polymorphic SNPs in flanking regions of a
linkage peak to increase allelic informativeness and where inter-
marker interval was greater than 1 cM. Twelve additional SNPs
with high heterozygosity in Caucasian Europeans (http://www.
internationalgenome.org/) were selected in 1q22–q24.2 (rs1002599,
rs1509022 and rs2134095), 7q31.2–q34 (rs6968786, rs6651125,
rs6953296 and rs447266) and 10q21.2–q23.1 (rs7893379,
rs2271698, rs12774070, rs3750736 and rs12263204). The fine-
mapping linkage analysis included 513 markers for chromosome
1,303 markers for chromosome 7, and 291 markers for chromo-
some 10 within 1-LOD-drop interval. The allelic frequencies of
markers used to perform the fine-mapping linkage analysis were
extracted from a Spanish control population of 629 individuals.34
After fine mapping, the relative family contribution to overall link-
age was computed using the –perFamily option in Merlin. Further
examination of the robustness of the three linkage peaks was
assessed through a replicative analysis using 10 sets of randomly
selected WES-derived markers from chromosome 1 (4,539 SNPs),
chromosome 7 (2,117 SNPs) and 10 (2,094 SNPs) that were
nonmonomorphic in the HapMap CEU population.
Rare variant selection
Different parameters were considered for variant annotation
including population frequency (1000 Genomes, Exome Vari-
ant Server, Exome Aggregation Consortium, Collaborative
Spanish Variant Server), functional consequences, pathogenic-
ity and position (SnpEff, ANNOVAR, dbNSFP).
Variant filtering was performed with an in-house pipeline
written in R language already described in previous studies.19,27
The parameters taken into account were sequencing quality (cov-
erage ≥10× and genotype quality ≥50), germline allelic frequency
(≤0.1% in ExAC database), internal cohort frequency (≤25%) and
functional effect (truncating or predicted disrupting missense var-
iants). Missense pathogenicity prediction was assessed with
PhyloP (score ≥1.6), SIFT (damaging), PolyPhen2 (probably or
possibly damaging), MutationTaster (disease-causing), LRT (dele-
terious) and CADD (score ≥15). Missense variants predicted to
be pathogenic in the least 3 out of 6 predictor tools were selected
for further analysis. Variants were also visually inspected with the
Integrative Genomics Viewer, and discarded if any sequencing
artifact due to strand bias was detected.35
Family-based association analysis for rare variants
A total of 91 rare and potentially disruptive variants regardless
their segregation status in the families from genes spanning the
three detected linkage intervals were included for a family-based
association test, using the gene-based segregation test (GESE)
package implemented in R (https://cran.r-project.org/web/
packages/GESE/).36 Segregation of rare variants was assessed
including all individuals diagnosed with CRC, high-risk adenoma
or other type of cancer sequenced in our study. Values of p for sta-
tistical significance were calculated after 100,000 simulations. Per-
family weights were included in the analysis to assess a relative
symptom severity variable based on the number of CRC patients
per family, age of onset and the presence of high-risk adenoma
and other extracolonic neoplasms.
Selection of novel candidate genes for CRC
The prioritization process was completed with the selection of
the putative candidate genes arising from the GESE family-
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based association analysis and their interaction partners. This
selection process was performed using the Ingenuity pathway
analysis (IPA) software program (Ingenuity Systems Inc., Red-
wood City, CA), which can identify significant networks using
a built-in scientific literature-based database.37 The associated
genes with unadjusted p-value < 0.05 from the family-based
analysis were used as input for IPA and combined with well-
known hereditary CRC genes (APC, MLH1, MSH2, MSH6,
PMS2, MUTYH, BMPR1A, BMP4, PTPRJ, GALNT12, EPHB2,
AXIN2, UNC5C, GREM1, STK11, SMAD4, PTEN, KLLN,
POLE, POLD1, BUB3, BUB1, BUB1B, RNF43, ATM, PALB2,
SEMA4A, RPS20, NTHL1, FAN1, MCM9, BLM, LRP6,
SMAD9, MSH3, EPCAM, SETD6 and BRF1) plus an addi-
tional 115 general cancer predisposition genes.38 Networks
containing any of the GESE genes were considered of interest.
Functional candidate gene presented here was (i) expressed
in colon tissue, using mRNA expression data from the GTEX
dataset (RPKM > 1) and protein expression from the Human
Protein Atlas; (ii) compatible with cancer predisposition based
on reviewing of bibliographic and functional data present in
different databases (NCBI, Gene Ontology, KEGG, Reactome).
Final candidate variant was confirmed by Sanger sequencing
(GATC Biotech, Germany).
Data availability
The data that support the findings of our study are available
from the corresponding author upon reasonable request.
Results
Linkage analysis
A genome-wide nonparametric linkage analysis was performed
using WES derived-genotype data from 18 multiplex and
extended families with unaffiliated strong CRC aggregation
(Fig. 1). The highest peak LOD scores were identified on three
loci: chromosome 1q22–q24.2 (with LODlinear = 2.11 and
LODexp = 1.872 at rs10753668 or 180.122 cM); chromosome
7q31.2–q34 (with LODlinear = 2.023 and LODexp = 1.838 at
rs2075371 or 142.05 cM); and chromosome 10q21.2–q23.1 (with
LODlinear = 1.423 and LODexp = 2.118 at rs1904589 or 94.855 cM;
Fig. 2). When additional markers were added to fine-map each
region and reduce intermarker intervals, evidence for linkage
at the 1q22–q24.2 locus increased to LODlinear = 2.383
(p-value = 4.6E−04) and LODexp = 2.196 (p-value = 7.3E−04)
with rs2134095 being the peak marker (Fig. 3a, Supporting Infor-
mation Table S1). Likewise, evidence for linkage at the 7q31.2–
q34 locus increased to LODlinear = 2.197 (p-value = 7.3E−04) and
LODexp = 2.149 (p-value = 8.2E−04) with rs6953296 being the
Figure 2. Results of the genome-wide linkage analysis. Nonparametric linkage analysis was performed under the linear (black line) and
exponential (red line) models in 18 multiplex/extended CRC families. Each chromosome is represented in a separate plot, including the X
chromosome. A linkage signal with LOD > 2 was observed at chromosomes 1q22–q24.2 with a maximum linear LOD score at marker
rs10753668 of 2.11 (linear model), 7q31.2–q34 with a maximum linear LOD score at marker rs2075371 of 2.023 (linear model) and
10q21.2–q23.1 with a maximum linear LOD score at marker rs1904589 of 2.118 (exponential model). Additional markers were subsequently
added to fine-map these linkage peaks.
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Figure 3. Schematic of the linkage intervals and the gene content between the proximal and distal boundaries on chromosome 1q22–q24.2
(a), 7q31.2–q34 (b) and 10q21.2–q23.1 (c) after fine mapping with 12 additional SNPs. The maximum LOD score under linear and
exponential models are shown at each locus. The locations of known protein-coding genes in the linkage interval are provided in the images
below which are generated using the UCSC genome browser (https://genome.ucsc.edu). Final candidate genes for CRC, after gene network
analysis, colon gene expression evaluation and sequence quality are highlighted using a red box.
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peak marker (Fig. 3b, Supporting Information Table S2). Finally,
evidence for linkage remained stable at the 10q21.2–q23.1 locus
(LODlinear = 1.455, p-value = 0.005; LODexp = 2.195, p-value =
7.3E−03) with rs1904589 remaining as the peak marker (Fig. 3c,
Supporting Information Table S3).
We examined the robustness of the observed linkage signals
using a replicative analysis, performing linkage analysis in 10 rep-
licate SNP sets using random markers from chromosome 1, 7
and 10 (Supporting Information Figs. S1–S3). The linkage peaks
previously identified were replicated in all of the 10 data sets
with a LOD > 2 under either the linear or the exponential
model, or both. These results suggest that the linkage to these
regions is not being driven by a particular set of SNPs and is
robust to SNP selection. A formal permutation analysis to
exclude false-positive signals and to determine empirical signifi-
cance was not possible, as all subjects were affected and permut-
ing the subjects’ phenotypes would be uninformative.
The CRC linkage intervals, as defined by a 1-LOD drop
interval, spanned a genetic distance of 20.955 cM (1q22–
q24.2), 18.339 cM (7q31.2–q34) and 20.214 cM (10q21.2–
q23.1). Per-family linkage analysis showed locus heterogene-
ity, whereby the number of CRC families contributing posi-
tively to the overall LOD score at 1q22–q24.2, 7q31.2–q34
and 10q21.2–q23.1, were 13, 14 and 12 families, respectively
(Supporting Information Table S4), and seven families con-
tributed to signals at all three peaks.
Family-based association analysis for rare variants under
specific linkage intervals
Next, we explored the possibility that rare alleles with higher
penetrance effects, explained the linkage peaks at each locus. We
extracted 530 single nucleotide variants (SNVs) from WES data
within 271 protein-coding genes under the linkage peak intervals
(Fig. 3). After quality control filters and more stringent selection
criteria, 89 SNVs from 78 genes were selected for segregation
analysis (Supporting Information Table S5).
Then, we performed a family-based segregation test of the
89 rare variants using the GESE package. Allele-frequency
weighted segregation analysis revealed significant rare variant
segregation with CRC in 18 genes (Table 1).
Novel candidate genes for CRC
Genes with evidence of familial segregation for rare pathogenic
variants in CRC patients were further inspected using a protein–
protein network analysis (IPA) to identify the most plausible can-
didate genes from the linkage peaks involved in hereditary CRC.
We pooled together the 18 genes with segregating variants from
Table 1. Family-based association test of rare variants under the
linkage peaks
Gene
SNVs/
Seg-SNV
Family
(patients
with
Seg-SNV) p-value
Weighted
p-value
Specific
LOD at
locus
NDST2 1/1 CRC-23 (3) 1.28E−08 2.00E−07 0.49
FAM78B 1/1 CRC-20 (2) 1.28E−08 2.00E−07 0.20
GRM8 1/1 CRC-1 (2) 2.56E−08 1.00E−07 0.29
SYNPO2L 1/1 CRC-11 (2) 2.56E−08 4.00E−07 0.30
COL13A1 1/1 CRC-11 (2) 2.56E−08 4.00E−07 0.30
ZSWIM8 1/1 CRC-9 (2) 1.99E−06 5.00E−06 0.47
MYPN 1/1 CRC-19 (3) 3.94E−06 4.90E−05 0.14
LMNA 1/1 CRC-9 (2) 2.18E−05 2.60E−05 0.47
WDR91 1/1 CRC-10 (2) 3.16E−05 6.00E−05 0.27
LY9 1/1 CRC-23 (3) 3.55E−05 3.90E−04 0.29
INSRR 1/1 CRC-7 (2) 4.74E−05 4.20E−04 0.29
TMEM79 1/1 CRC-5 (3) 1.26E−04 4.50E−04 −0.003
SMO 1/1 CRC-13 (3) 1.77E−04 6.90E−04 0.14
C1orf85 1/1 CRC-4 (2) 3.06E−04 3.08E−03 0.20
CDH23 4/1 CRC-8 (3) 2.97E−04 3.00E−03 0.59
TNPO3 1/1 CRC-11 (2) 4.71E−04 4.74E−03 0.30
CFTR 1/1 CRC-20 (2) 7.52E−04 7.47E−03 0.19
VCL 2/1 CRC-10 (2) 9.15E−04 2.88E−03 0.30
Results of 89 rare variants (SNVs) segregating with patients (Seg-SNV)
across the 18 CRC families (n = 47 patients), after simulations and weight
corrections. Only significant genes (p-value < 0.05) are reported.
Abbreviations: SNVs, number of SNVs regardless segregation in CRC
patients; Seg-SNV, number of SNVs segregating in all CRC patients in this
family. Specific LOD, linkage contribution from this gene to a spe-
cific peak.
Table 2. Candidate genes within regions with positive linkage on chromosomes 1, 7 and 10 after considering hereditary cancer networks
Gene Variant Family
Chromosomal
region
Colon gene
expression (RPKM) IGV Gene function/OMIM
LMNA c.1718C>T (p.Ser573Leu) CRC-9 1q22–q24.2 52 + Muscular dystrophies
SMO c.1921C>G (p.Pro641Ala) CRC-13 7q31.2–q34 5.4 + Familial or sporadic basal cell
carcinoma/Curry–Jones syndrome
WDR91 c.699G>A (Asp239Tyr) CRC-10 7q31.2–q34 4.6 + Neuronal development
CDH23 c.4885A>C (p.Ile1629Leu) CRC-8 10q21.2–q23.1 0.6 + Deafness
VCL c.590C>T (p.Thr197Ile) CRC-10 10q21.2–q23.1 101 + Cardiomyopathy
Information about the identified genetic variant, the CRC family, gene expression level in colon, sequence quality, gene function and previous involve-
ment in hereditary conditions are listed.
Abbreviations: CRC, colorectal cancer; IGV, integrative genomics viewer: + validated, − not validated; OMIM, online Mendelian inheritance in man, www.
omim.org; RPKM, reads per kilobase per million mapped reads (from the Human Protein Atlas, GTEx dataset-colon); Curry-Jones syndrome, craniofacial
malformations, polysyndactyly, abnormal skin and gut development.
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the GESE analysis with established genes for hereditary CRC
(38 genes) and germline predisposition to cancer (115 genes) to
investigate specific CRC networks. Six networks were produced
and two of them contained GESE genes. Potential CRC candidate
genes were prioritized as functionally plausible when a network
contained them (Supporting Information Fig. S4). This procedure
resulted in the retention of five candidate genes listed in Table 2 to
which further exclusion criteria were applied. Candidate genes
with negligible expression in colon tissue were excluded (CDH23).
Only genes with a function compatible with cancer predisposition
were retained. Two genes were disregarded due to their involve-
ment in the predisposition to diseases not related to cancer
(LMNA, muscular dystrophy;VCL, cardiomyopathy) or for a gene
function that was not tumor-related (WDR91, neuronal develop-
ment). Accordingly, SMO remained as a plausible candidate to be
involved in germline predisposition to familial CRC although evi-
dence from further studies is needed.
Discussion
Inherited variants are considered to be the underlying cause in an
important number of CRC cases,1,2 with familial aggregation esti-
mated to be present in up to 35% of CRC patients. During the past
40 years, several approaches have been used to identify genetic
factors causing this hereditary predisposition. In Mendelian disor-
ders, linkage analysis has been the only approach used for decades
and has reported numerous examples of gene discovery.39 The use
of large families in these linkage studies permitted the identifica-
tion of the main hereditary genes (APC and the DNA mismatch
repair genes). Linkage approaches have also been applied using
nonparametric models in complex disorders, and CRC linkage
studies have identified several susceptibility loci at chromosomes
9q22–q31.2,4 3q22,5 11q, 14q, 22q,6 3q29, 4q31.3, 7q31,7 10q23,8
4q21, 8q13, 12q24, 15q22,9 4p16.3, 9q31.1, 17p13.2 and
Xp22.33.10 However, apart from previously commented successful
examples, linkage studies in CRC have rarely converged on the
same top results, and more generally association studies in linkage
regions have failed to identify common variants implicated in the
disorder.40 Subsequently, linkage studies have been superseded by
genome-wide association studies (GWAS), which have been able
to identify low-risk genetic variants.11 However, variants identified
by GWAS only explain approximately 10% of the variance in
genetic liability to CRC,12 suggesting that rare variants with higher
penetrance effects may play a substantial role in disease, particu-
larly in familial forms.
The discovery of high-penetrance germline variants in CRC
genes is feasible using NGS technologies. Recently, WES studies
performed in approximately 2,000 familial or early-onset CRC
cases suggested candidate genes harboring potential pathogenic
rare variants.18–21,41 Despite the encouraging results, the number
of identified causative genes has remained limited and poorly rep-
licated. In a previous study, we performedWES in our unaffiliated
familial CRC cohort of 71 patients from 38 families that led to the
identification of potential candidate genes including CDKN1B,
XRCC4, EPHX1, NFKBIZ, SMARCA4 and BARD119 and a
Fanconi anemia pathway enrichment.27 WES data have also been
used to infer rare copy number variants that could act as the
germline mutational event in some families.28
After more than a decade, linkage analysis has re-emerged as
a successful approach to uncover genes implicated in Mendelian
diseases when used in combination with NGS.26,42–44 This
approach has also been recently applied in complex disorders
where susceptibility loci are examined for rare variants with
higher penetrance effects that are expected to segregate among
patients in large families. This combined strategy has been
employed in large individual families or few combined families
in some complex disorders,24,25,45,46 but has never been applied
in multiplex or extended families with cancer. Our study is the
first to employ linkage and WES data in cancer families by
examining 47 patients from 18 extended CRC families.
We identified three suggestive linkage peaks on chromosomes
1q22–q24.2, 7q31.2–q34 and 10q21.2–q23.1. Two of our CRC
susceptibility loci overlap with previously identified linkage
regions at 7q31 and 10q23.7,8 Neklason et al. performed a
genome-wide scan in 151 DNA samples from 70 families which
implicated chromosome 7q31, whereas Nieminen et al. per-
formed a linkage scan in a large Finnish CRC type X family that
yielded a suggestive signal on 10q23, and BMPR1A was
suggested as causative gene. Our findings provide additional evi-
dence in support of these previous results implicating 7q31.2–
q34 and 10q21.2–q23.1 in the germline predisposition to CRC.
Segregation analysis for potentially pathogenic rare variants
inherited by CRC patients followed by a protein network analysis
identified SMO as the most relevant candidate for germline CRC
predisposition, which lies in the center of the 7q31.2–q34 linkage
peak. The SMO protein is a G-coupled receptor that interacts
with the patched protein, a receptor for hedgehog proteins. Alter-
ations in the SMO gene have been related to the familial or spo-
radic forms of basal cell carcinoma,47 and Curry–Jones
syndrome, a multisystem disorder characterized among other
symptoms by skin lesions, polysyndactyly, brain malformations
and intestinal malrotation with myofibromas or hamartomas.48 It
is possible that finding a rare variant in SMO is due to chance,
given the limited number of available affected subjects in the fam-
ily with the segregating variant and the absence of segregating
SMO variants in other families showing linkage to 7q31.2–q34,
although this may also indicate locus heterogeneity.
The interesting findings presented in our study must be
considered in light of the limitations that were present. First,
we did not account for the potential contribution of common
variants associated with CRC. However, it could be argued
that common variants may have a reduced impact on multi-
plex families with segregating illness. Second, while rare vari-
ants from noncoding regions are not covered in WES studies
(and are potentially more difficult to ascribe functional rele-
vance than those observed in protein-coding regions), they
may explain additional contribution to the observed linkage
intervals. Third, predictions of pathogenicity from variants at
untranslated regions are not as reliable as predictions based
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on missense variants, so while we considered only predicted
pathogenic rare variants from coding regions, we could not
exclude etiologic variants from those regions not examined
here. Finally, while we considered multiplex families with high
rates of cancer, most families had only 2–3 patients with
DNA available and many of those were close relatives, so the
power to detect significant linkage was low. Furthermore, the
power of segregation analysis of individual rare variants in
small families is limited, and presence of phenocopies within
a family would impact the interpretation of apparent non-
segregation of potentially pathogenic variants, thus rare vari-
ants in other genes within the 7q31.2–q34 linkage interval
should not be discounted. The identification and analysis of
more distally related affected relatives from these and other
families may yield more information on these and other risk
loci for CRC. While we considered only rare protein-coding
variants predicted to be pathogenic with perfect segregation
with CRC in these multiplex/extended families in defining the
most likely candidate gene, we cannot exclude the contribu-
tion of pathogenic variants that partly segregate with the phe-
notype, given the allelic heterogeneity observed in CRC.
In summary, we performed a genome-wide linkage analysis
using WES-derived genotype data from 18 multiplex and
extended families with unaffiliated strong CRC aggregation and
found suggestive risk loci on chromosomes 1q22–q24.2, 7q31.2–
q34 and 10q21.2–q23.1. Rare variant segregation analysis and
protein network analyses identified SMO as a plausible candidate
for germline CRC predisposition. Replication in additional
cohorts (including targeted sequencing of large numbers of fami-
lies with hereditary CRC) and further functional studies are
required to confirm this novel potential candidate for CRC
germline predisposition. The present approach can be used with
already available NGS data from families with several sequenced
members to further identify candidate genes involved germline
predisposition to the disease.
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